Ipratropium Bromide and Tiotropium Bromide

Mechanism of action and effect on the respiratory system

Both drugs act by blocking muscarinic cholinergic receptors. The main pharmacological effect in the respiratory system is pronounced bronchodilation. The drugs block $M_3$ muscarinic receptors located on smooth muscle cells, predominantly in large and medium bronchi, which leads to the relief of spasm and expansion of the airways.

In addition to affecting muscle tone, these agents affect the bronchial glands. They effectively reduce their secretion. From a clinical perspective, this is a dual process:

• On the one hand, the amount of secreted mucus decreases.
• On the other hand (and this is a significant clinical drawback), the total volume of sputum decreases, and it becomes significantly more viscous, which seriously complicates its clearance and expectoration.

Despite the thickening of sputum, the drugs have an important positive property: they do not suppress mucociliary clearance at all. The transport function of the ciliated epithelium in the bronchi remains intact.

What is the difference between ipratropium and tiotropium?

Although both substances belong to the same pharmacological group, there is a critical difference between them in receptor profile and selectivity of action.

Ipratropium bromide is a non-selective agent. It blocks all muscarinic receptor subtypes ($M_1$, $M_2$, $M_3$). Its binding to presynaptic $M_2$ receptors on nerve endings leads to an undesirable phenomenon: the release of the neurotransmitter acetylcholine is disinhibited and increased. This excess acetylcholine enters the synaptic cleft, where it begins to directly compete with ipratropium molecules, displacing the drug from the receptors. As a result, the efficacy of the drug may be limited.

Tiotropium bromide, in contrast, has kinetic selectivity. It reliably blocks $M_1$ and $M_3$ receptors of the airways while "sparing" (not blocking) presynaptic $M_2$ muscarinic receptors. Due to this, excess acetylcholine is not released into the synaptic cleft. In addition, the drug dissociates very slowly from receptors, providing a prolonged and sustained effect (up to 24 hours vs. 6–8 hours for ipratropium).

Pharmacokinetics and safety profile

In terms of physicochemical properties, both ipratropium and tiotropium are quaternary ammonium compounds. This means they are strictly hydrophilic (polar) substances with low lipophilicity.

Upon inhalation, the distribution of the drug occurs as follows:

• Only about 10% of the administered dose reaches the small bronchi and alveoli.
• The remaining major part of the drug is deposited in the oropharynx and subsequently swallowed by the patient.

However, due to their pronounced polarity, these compounds penetrate biological membranes extremely poorly. They are practically not absorbed into the blood either from the mucous membranes of the respiratory tract or from the intestine upon swallowing.

The consequence of such low systemic absorption is high safety: typical systemic (atropine-like) side effects are practically absent. Only local reactions occur: dry mouth (the result of salivary gland suppression) and increased sputum viscosity.

Clinical applications

The main area of application for inhaled anticholinergics is pulmonology. They are used for obstructive airway diseases and bronchial asthma.

Special role in COPD: These agents are the drugs of choice. In the pathogenesis of chronic obstructive pulmonary disease, a key role is played by the pathological increase in the cholinergic influence of the vagus nerve on bronchial tone. Anticholinergics specifically and effectively relieve this influence.

• Ipratropium bromide starts acting 15 minutes after inhalation.
• Tiotropium bromide (a long-acting drug) has a slower onset, but is prescribed once daily specifically to prevent prolonged exacerbations.

Additional indications:

1. ENT practice: Ipratropium is used as a spray for vasomotor rhinitis to reduce rhinorrhea (suppresses the secretion of nasal mucosa glands).
2. Cardiology: The drug "Itrop" (ipratropium bromide for intravenous and oral administration) is used for sinus bradycardia and heart blocks caused by excessive vagal influence, as it increases heart rate and atrioventricular conduction.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Pathogenesis of COPD: why increased vagus nerve tone plays a key role.
• Pharmacodynamics of quaternary ammonium compounds: the relationship between molecule structure and membrane permeability.
• Agents for the treatment of overactive bladder (detrusor hyperactivity).
• Use of anticholinergics in cardiology (management of vagal bradyarrhythmias).

Other topics in the section «Drugs acting on cholinergic synapses»

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.